BioCentury | Mar 5, 2021
Politics, Policy & Law

It’s complicated: generics companies want FDA to simplify path for complex generics

...than outcome gains.”Industry wants early, consistent guidanceGeneric drug companies believe that uncertain and shifting regulatory sands...
BioCentury | Feb 11, 2021
Product Development

Feb. 10 Quick Takes: Softly goes PacBio; plus PGDx, Nuvation Bio, Gamida, Portal Innovations

...and existing investors that participated included Northpond Ventures, Vensana Capital, Rock Springs Capital, Kern Capital, Sands...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...publication. Joining Khosla Ventures in the $40 million round were Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands...
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...Management, Osage University Partners and Asymmetry Capital Management, as well as existing investors Northpond Ventures, Sands...
BioCentury | Dec 5, 2020
Politics, Policy & Law

Trump administration uses last days to undermine public health agencies

Senior Trump administration officials are spending their last weeks in office throwing sand into the gears of government, gumming up the operation of public health agencies and dismantling protections against political interference in the actions...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

Blueprint gains broader FDA label for Gavreto FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDA:BLUE) to treat advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory thyroid cancer in patients at...
BioCentury | Dec 1, 2020
Product Development

Moderna moves & Immunocore breaks through: a BioCentury podcast

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...that bind undisclosed new E3 ligases.Nurix CEO Arthur Sands said...
...strategy for viral replication,” said CEO Arthur Sands.In...
BioCentury | Sep 1, 2020
Product Development

COVID-19 Quick Takes: AZ starts pivotal study of vaccine as Pfizer, BioNTech pass two-thirds enrollment mark

AZ begins U.S. Phase III vaccine studyAstraZeneca plc (LSE:AZN; NYSE:AZN) announced Monday the beginning of the 30,000-volunteer U.S. Phase III D8110C00001 trial of AZD1222 to prevent COVID-19. The U.S. Biomedical Advanced Development Authority (BARDA) is...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...Life Sciences Fund led the round, with participation from Andera Partners, Brace Pharma Capital, Green Sands...
Items per page:
1 - 10 of 137
BioCentury | Mar 5, 2021
Politics, Policy & Law

It’s complicated: generics companies want FDA to simplify path for complex generics

...than outcome gains.”Industry wants early, consistent guidanceGeneric drug companies believe that uncertain and shifting regulatory sands...
BioCentury | Feb 11, 2021
Product Development

Feb. 10 Quick Takes: Softly goes PacBio; plus PGDx, Nuvation Bio, Gamida, Portal Innovations

...and existing investors that participated included Northpond Ventures, Vensana Capital, Rock Springs Capital, Kern Capital, Sands...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...publication. Joining Khosla Ventures in the $40 million round were Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands...
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...Management, Osage University Partners and Asymmetry Capital Management, as well as existing investors Northpond Ventures, Sands...
BioCentury | Dec 5, 2020
Politics, Policy & Law

Trump administration uses last days to undermine public health agencies

Senior Trump administration officials are spending their last weeks in office throwing sand into the gears of government, gumming up the operation of public health agencies and dismantling protections against political interference in the actions...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

Blueprint gains broader FDA label for Gavreto FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDA:BLUE) to treat advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory thyroid cancer in patients at...
BioCentury | Dec 1, 2020
Product Development

Moderna moves & Immunocore breaks through: a BioCentury podcast

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...that bind undisclosed new E3 ligases.Nurix CEO Arthur Sands said...
...strategy for viral replication,” said CEO Arthur Sands.In...
BioCentury | Sep 1, 2020
Product Development

COVID-19 Quick Takes: AZ starts pivotal study of vaccine as Pfizer, BioNTech pass two-thirds enrollment mark

AZ begins U.S. Phase III vaccine studyAstraZeneca plc (LSE:AZN; NYSE:AZN) announced Monday the beginning of the 30,000-volunteer U.S. Phase III D8110C00001 trial of AZD1222 to prevent COVID-19. The U.S. Biomedical Advanced Development Authority (BARDA) is...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...Life Sciences Fund led the round, with participation from Andera Partners, Brace Pharma Capital, Green Sands...
Items per page:
1 - 10 of 137